ClassID:

170432

G01N2333/5434 - CPC Classification

Classification description:

Assays involving biological materials from specific organisms or of a specific nature from animals; from humans; Assays involving cytokines; Interleukins [IL] IL-12

Recent Application in this class:
#1
20260124150
2026-05-07

USE OF MONOLITHIC ANION EXCHANGE CHROMATOGRAPHY AND LIGHT SCATTERING FOR QUANTIFYING EXTRACELLULAR VESICLES

#2
20260049998
2026-02-19

METHODS OF DETECTING AND TREATING CEREBRAL ANEURYSMS

#3
20260023085
2026-01-22

COMPOSITIONS AND METHODS FOR ANALYSIS, DETECTION, AND TREATMENT OF MULTIPLE SCLEROSIS

#4
20250347700
2025-11-13

METHODS OF DETECTING AND TREATING CEREBRAL ANEURYSMS

#5
20250334586
2025-10-30

Methods, Kits and Compositions for Assessing and Treating Interstitial Cystitis

#6
20250319091
2025-10-16

TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS

#7
20250314662
2025-10-09

NOVEL CYTOKINE-BASED THERAPIES AND METHODS

#8
20250224392
2025-07-10

METHOD FOR EVALUATING QUALITY OF INDUCEMENT INHIBITORY-T-CELL FORMULATION

#9
20240350551
2024-10-24

TREATMENT OF AGING FRAILTY COMPRISING ADMINISTERING BONE MARROW DERIVED MESENCHYMAL STEM CELLS

#10
20240342474
2024-10-17

VAGUS NERVE STIMULATION PRE-SCREENING TEST

#11
20240219385
2024-07-04

MOLECULAR SIGNATURES OF LONG-TERM COVID-19 AND TREATMENT THEREOF

#12
20240183867
2024-06-06

INDIRECT HOMOGENEOUS MOBILITY SHIFT ASSAYS FOR THE DETECTION OF BIOLOGICS IN PATIENT SAMPLES

#13
20230078652
2023-03-16

METHODS FOR PREDICTION OF ANTI-TNF ALPHA DRUG LEVELS AND AUTOANTIBODY FORMATION

#14
20220357329
2022-11-10

PREDICTIVE LIQUID MARKERS FOR CANCER IMMUNOTHERAPY

#15
20220341946
2022-10-27

BIOMARKERS FOR ASSESSING EXPLANT ORGAN VIABILITY

#16
20220257670
2022-08-18

METHODS AND PRODUCTS FOR TREATMENT OF GASTROINTESTINAL DISORDERS

#17
20220082572
2022-03-17

USE OF PERIPHERAL BLOOD PRO- AND ANTI-INFLAMMATORY CYTOKINE RATIOS AS MARKERS OF IMPLANTATION PRECEDING PREGNANCY

#18
20220064246
2022-03-03

NOVEL CYTOKINES AND USE THEREOF

#19
20220050119
2022-02-17

BIOMARKERS

#20
20220040483
2022-02-10

Vagus nerve stimulation pre-screening test

#21
20210347887
2021-11-11

COMPOSITIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSE

#22
20210285964
2021-09-16

Atypical hemolytic uremic syndrome (AHUS) biomarker proteins

#23
20210063413
2021-03-04

DENDRITIC CELL POTENCY ASSAY

#24
20210060022
2021-03-04

Treatment of cancers using PI3 kinase isoform modulators

#25
20210018515
2021-01-21

BIOMARKER COMBINATION FOR IDENTIFICATION OF "AT-RISK" SUBJECTS FOR AKI

#26
20200284805
2020-09-10

Biomarkers related to organ function

#27
20200158725
2020-05-21

Methods for prediction of anti-TNF α drug levels and autoantibody formation

#28
20200088749
2020-03-19

Indirect homogeneous mobility shift assays for the detection of biologics in patient samples

#29
20200040076
2020-02-06

COMPOSITIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSE

#30
20200024343
2020-01-23

COMPOSITIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSE

#31
20190169290
2019-06-06

COMPOSITIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSE

#32
20190072561
2019-03-07

Methods and compositions for the diagnosis and treatment of cancer

#33
20190046799
2019-02-14

Vagus nerve stimulation pre-screening test

#34
20180364229
2018-12-20

Biomarkers for assessing risk of transitioning to systemic lupus erythematosus classification and disease pathogenesis

#35
20180327843
2018-11-15

Use of IL-3, IL-33 and IL-12p40 as markers for characterization of respiratory infections by respiratory syncytial virus

#36
20180156784
2018-06-07

Immune profiling and minimal residue disease following stem cell transplantation in multiple myeloma

#37
20180128833
2018-05-10

METHODS OF TREATING WITH TUMOR MEMBRANE VESICLE-BASED IMMUNOTHERAPY AND PREDICTING THERAPEUTIC RESPONSE THERETO

#38
20180015093
2018-01-18

TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS

#39
20170363640
2017-12-21

Biomarker for diagnosing vascular diseases and the uses thereof

#40
20170328923
2017-11-16

Indirect homogeneous mobility shift assays for the detection of biologics in patient samples

#41
20170315117
2017-11-02

Methods for prediction of anti-TNFα drug levels and autoantibody formation

#42
20170269102
2017-09-21

ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS) BIOMARKER PROTEINS

#43
20170196950
2017-07-13

METHOD FOR PRODUCING AUTOLOGOUS TOLEROGENIC DENDRITIC CELLS (TOLDCS) WITH SPECIFIC ANTIGENS AND THEIR USE IN THE PREPARATION OF A MEDICAMENT USEFUL FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

#44
20170114112
2017-04-27

Epitope recognized by anti-interferon gamma autoantibodies in patients with disseminated mycobacterial infections and the application therefor

#45
20170059581
2017-03-02

METHODS FOR DIAGNOSIS AND PROGNOSIS OF INFLAMMATORY BOWEL DISEASE USING CYTOKINE PROFILES

#46
20170030927
2017-02-02

METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE

#47
20170023590
2017-01-26

Atypical hemolytic uremic syndrome (aHUS) biomarker proteins

#48
20170002073
2017-01-05

Compositions and methods for modulating an immune response

#49
20160274097
2016-09-22

Sample analysis systems and methods

#50
20160231330
2016-08-11

Biomarkers related to organ function

#51
20160169901
2016-06-16

METHODS FOR DIAGNOSIS OF CUTANEOUS T-CELL LYMPHOMA

#52
20160154009
2016-06-02

Atypical hemolytic uremic syndrome (AHUS) biomarker proteins

#53
20160131657
2016-05-12

Methods and compositions for the diagnosis and treatment of cancer

#54
20160054336
2016-02-25

Methods and compositions for diagnosis and prognosis of renal injury and renal failure

#55
20160025705
2016-01-28

Process for assessing risk of substance administration

#56
20150301066
2015-10-22

Biomarkers for the identification of liver damage

#57
20150212090
2015-07-30

Use of a panel of urinary cytokines to predict response to BCG therapy for bladder cancer

#58
20150177250
2015-06-25

DETERMINATION OF EFFICIENT TIME(S) FOR CHEMOTHERAPY DELIVERY

#59
20150105289
2015-04-16

BIOMARKERS FOR LOWER URINARY TRACT SYMPTOMS (LUTS)

#60
20140369998
2014-12-18

Biomarkers for Tuberculosis and HIV/AIDS

#61
20120269825
2012-10-25

METHODS OF MODULATING THE OX40 RECEPTOR TO TREAT CANCER

#62
20120087902
2012-04-12

Therapeutic Use Of Probiotics

#63
20110306063
2011-12-15

Methods and compositions for diagnosis and prognosis of renal injury and renal failure

#64
20110045522
2011-02-24

METHODS FOR DIAGNOSING DIABETES AND DETERMINING EFFECTIVENESS OF TREATMENTS

#65
20110008368
2011-01-13

METHODS OF MODULATING THE OX40 RECEPTOR TO TREAT CANCER

#66
20080279813
2008-11-13

Cd4+ Cd25+ T-cells activated to a specific antigen

#67
20080138833
2008-06-12

METHODS AND COMPOSITIONS FOR ASSESSING IL-12 OR THE NEUTRALIZATION OF IL-12 IN A SAMPLE